Clonidine Suppression Testing in Essential Hypertension

  1. DAVID S. GOLDSTEIN, M.D., Ph.D;
  2. PAUL D. LEVINSON, M.D.;
  3. REUVEN ZIMLICHMAN, M.D.;
  4. ARTHUR PITTERMAN, M.D.;
  5. ROBIN STULL; and
  6. HARRY R. KEISER, M.D.
  1. Bethesda, Maryland

    Abstract

    To assess the contribution of sympathetic outflow to blood pressure in patients with essential hypertension, we measured blood pressure and plasma norepinephrine responses to clonidine, an antihypertensive agent that decreases central sympathetic outflow, in 44 patients and in 41 normotensive control subjects of similar age. Among the hypertensive patients, the resting level of plasma norepinephrine was significantly related to the decrease in mean arterial pressure 3 hours after a single oral dose of clonidine, 300µg (r=0.62, p < 0.001). The magnitude of the depressor response in the patients also was correlated significantly with the decrease in plasma norepinephrine after clonidine (r=0.60, p < 0.001). These results suggest that increased sympathetic outflow plays a pathophysiologic role in some patients with essential hypertension.

    Article and Author Information

    • ▸From the Hypertension-Endocrine Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda, Maryland.

    • ▸Requests for reprints should be addressed to David S. Goldstein, M.D., Ph. D.; Building 10, 8C118, National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda, MD 20205.

    « Previous | Next Article »Table of Contents